Applied Therapeutics Logo
US03828A1016
A2PHHB
APLT

Applied Therapeutics

Chargement des cours...

Prévisions

L'objectif de cours moyen des analystes est de 0,23 € (+163,46 %). La médiane est de 0,23 € (+163,46 %).

Acheter
  5
Conserver
  5
Vendre
  1

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Applied Therapeutics delisted from Nasdaq after takeover by Cycle Group

    Applied Therapeutics has completed its merger with Cycle Group Holdings and is now an indirect wholly owned subsidiary of Cycle Group. Cycle Group subsidiary AT2B acquired all outstanding shares for $0.088 per share; shareholders also received a non-tradable CVR with potential payments of up to $0.40. Applied filed to suspend trading, delist and deregister with the SEC; the board and several executives resigned, and James Harrison took over leadership. Cycle is integrating the lead drug candidate Govorestat into its portfolio; analysts sharply cut ratings and price targets for Applied stock following the transaction. » Plus sur de.investing.com


  • Cycle extends takeover offer for Applied Therapeutics

    Cycle Group Holdings has extended the deadline for its takeover offer for Applied Therapeutics to 11:59 p.m. ET on January 29, 2026. Cycle is offering $0.088 per share in cash plus a non-tradable contingent value right; the price is close to the stock’s 52-week low. The board of directors of Applied Therapeutics unanimously recommends tendering the shares and warns that, if tendering is insufficient, liquidation and the immediate repayment of an $8.5 million promissory note to Cycle would likely follow. Financial data show a weak financial picture with negative EBITDA and significant financial challenges for Applied Therapeutics. » Plus sur de.investing.com


  • Applied Therapeutics explores strategic alternatives and cuts 46% of workforce

    Applied Therapeutics has launched a process to evaluate strategic options such as M&A, partnerships and licensing agreements to maximize shareholder value. At the same time, the company is reducing costs by cutting 46% of its workforce; it did not disclose exact employee numbers. The stock fell sharply last year and the company reported a negative EBITDA of USD 99.61 million, but says it has more cash than debt. Applied Therapeutics is reviewing FDA Type C meeting minutes for its lead candidate govorestat and considering next steps, after also agreeing a $75 million share sale facility with Cantor Fitzgerald. » Plus sur de.investing.com


  • Applied Therapeutics stock plunges after uncertainty in FDA approval process for Govorestat

    Applied Therapeutics shares fell about 55% in pre-market trading after the company said the next steps for a Govorestat approval filing, including a potential accelerated submission, have not been determined. Applied is waiting for the official FDA meeting minutes to decide how to proceed; it had previously aimed for a submission in Q3 2025. Govorestat is being developed to treat the rare neuropathy CMT‑SORD and already has multiple regulatory special designations in the US and Europe. » Plus sur de.investing.com


  • FDA discussion on Govorestat sends Applied Therapeutics stock sharply higher

    Applied Therapeutics completed a meeting with the FDA about a potential regulatory filing for Govorestat to treat CMT‑SORD. The stock jumped sharply after investors learned of the discussion; the company is now waiting for the official meeting minutes before determining next steps. Govorestat has orphan drug status from the FDA and EMA and is also being developed for other rare diseases. Applied Therapeutics has also entered an agreement for an at‑the‑market equity offering of up to USD 75 million to raise capital. » Plus sur de.investing.com

Données financières de l'entreprise

Au dernier trimestre, Applied Therapeutics a réalisé un chiffre d'affaires de 852,13 k € et un bénéfice net de -16,18 M €
(EUR) septembre 2025
YoY
Chiffre d'affaires 852,13 k -
Bénéfice brut 852,13 k -
Bénéfice net -16,18 M -
EBITDA -16,09 M -

Données fondamentales

Indicateur Valeur
Capitalisation boursière
13,51 M €
Nombre d'actions
144,3 M
Plus haut/bas sur 52 semaines
1,36 € - 0,0818 €
Dividendes Non
Bêta
2,08
Ratio P/E
-0,37
Ratio PEG
0,00
Ratio P/B
-26,72
Ratio P/S
14,86

Profil de l'entreprise

Applied Therapeutics, Inc., une société biopharmaceutique au stade clinique, développe de nouveaux produits destinés à traiter les maladies cardiovasculaires, la galactosémie et les complications diabétiques. Son candidat-médicament principal est l'AT-007, qui a achevé la phase 1/2 pour le traitement de la galactosémie chez des volontaires sains et des adultes, et qui fait également l'objet d'une étude clinique pédiatrique pour le traitement de la galactosémie chez les enfants ; il est également évalué pour le traitement du déficit en sorbitol déshydrogénase et pour le traitement de l'enzyme phosphomannomutase-CDG. La société développe également l'AT-001, qui est en essais cliniques de phase III pour le traitement de la cardiomyopathie diabétique, ainsi que pour le traitement de la neuropathie périphérique diabétique. Ses produits au stade préclinique comprennent l'AT-003 pour le traitement de la rétinopathie diabétique ; et l'AT-104, un inhibiteur de PI3K destiné au traitement de la leucémie lymphoblastique aiguë à cellules T, une hémopathie maligne orpheline. Applied Therapeutics, Inc. a été constituée en 2016 et a son siège social à New York, New York.

Nom
Applied Therapeutics
PDG
Les D. Funtleyder
Siège social New York City, ny
États-Unis
Site web
Secteur
Matériaux
Industrie
Produits chimiques
Introduction en bourse
14/05/2019
Employés 35

Symboles boursiers

Bourse Symbole
NASDAQ
APLT
Frankfurt
2UV.F
Düsseldorf
2UV.DU
München
2UV.MU
🍪

Parqet  utilise des cookies. En savoir plus